Molecular targeted therapies in head and neck cancer--an update of recent developments-.
Targeted therapies have made their way into clinical practice during the past decade. They have caused a major impact on the survival of cancer patients in many areas of clinical oncology and hematology. Indeed, in some hematologic malignancies, such as chronic myelogenous leukemia or non-Hodgkin's lymphomas, biologicals and antibodies specifically designed to target tumour-specific proteins have revolutionized treatment standards. In solid tumours, new drugs targeting EGF- or VEGF- receptors are now approved and are entering clinical practise for treatment of colon, lung, kidney and other cancers, either alone or in combination with conventional treatment approaches. Recent data have now shown that molecular targeted therapy might display efficacy in patients with head and neck squamous cell carcinoma (HNSCC) as well. The evaluated biologicals are generally well tolerated from HNSCC patients, who usually have the burden of multiple co-morbidities that interfere with conventional systemic treatment options. Therefore, molecular targeted therapies offer new treatment options even for heavily pretreated and seriously ill patients usually unable to tolerate chemotherapy or radiation therapy. The two most promising and advanced strategies are the blockage of growth-factor based cellular signalling and interference with angiogenesis-related pathways. But inhibitors of alternative targets, such as Scr and proteasomes, have already been evaluated in early clinical trials with HNSCC patients.
Goerner
Martin
M
Community Hospital Bielefeld, Department of Hematology, Oncology and Palliative Care, Teutoburger Str, 60, 33604 Bielefeld, Germany. martin.goerner@klinikumbielefeld.de
Seiwert
Tanguy Y
TY
Sudhoff
Holger
H
D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000378:metabolism*
D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor
Cancer Res. 1999 Apr 15;59(8):1935-40
10213503
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32
16203784
Cancer. 2008 Jun 15;112(12):2710-9
18481809
Lancet Oncol. 2010 Jan;11(1):21-8
19897418
Expert Opin Biol Ther. 2009 May;9(5):667-74
19379120
Oral Oncol. 2008 Apr;44(4):361-8
17689285
Clin Oncol (R Coll Radiol). 2005 Sep;17(6):418-24
16149284
Eur J Cancer. 2008 Sep;44(13):1922-30
18691881
Curr Opin Mol Ther. 2009 Jun;11(3):308-21
19479664
N Engl J Med. 2006 Feb 9;354(6):567-78
16467544
Semin Oncol. 2008 Jun;35(3):274-85
18544442
Semin Oncol. 2008 Jun;35(3):286-97
18544443
Nature. 1993 Apr 29;362(6423):841-4
7683111
J Clin Oncol. 2007 Aug 20;25(24):3766-73
17704426
Cancer Res. 1993 Aug 1;53(15):3579-84
8339264
J Clin Oncol. 2006 Jun 10;24(17):2666-72
16763281
Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1458-65
16488554
Annu Rev Med. 2009;60:207-19
19630571
Ann Oncol. 2010 Apr;21(4):864-870
19850643
Ann Oncol. 2010 Feb;21(2):342-347
19892746
J Immunol. 2004 Oct 1;173(7):4699-707
15383606
Expert Rev Anticancer Ther. 2009 Oct;9(10):1421-8
19828002
Cancer Res. 2004 Sep 1;64(17):6166-73
15342401
J Clin Oncol. 2003 Jul 15;21(14):2787-99
12860957
J Clin Oncol. 2009 Apr 10;27(11):1864-71
19289630
Head Neck Oncol. 2009 Oct 14;1:36
19828033
Cancer Biol Ther. 2009 Apr;8(8):696-703
19276677
Oncologist. 2009 Mar;14(3):284-90
19282350
Br J Cancer. 2009 May 5;100(9):1379-84
19401697
Lancet Oncol. 2009 Mar;10(3):247-57
19201650